Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib

International Journal of Molecular Sciences(2020)10.3390/ijms21072337Source: DataRank Database

Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib is a research paper published in International Journal of Molecular Sciences (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: goldTopics (51)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Zhijian Jin ORCID,Xin Lü ORCID,Guoqiang Liu ORCID

Live enrichment

PubMed:32230980 PMC:PMC7178187

Congressionally Directed Medical Research Programs

Grant: W81XWH-14-1-0576

National Institutes of Health

Grant: KL2 TR002530 and UL1 TR002529

Boler Family Foundation

Grant: Research support

University of Notre Dame

Grant: Integrated Biomedical Sciences Graduate Program

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: R50 CA221675

National Institutes of Health

Grant: 5KL2TR002530-04

Institutional Career Development Core

National Institutes of Health

Grant: 5UL1TR002529-02

Indiana Clinical and Translational Sciences Institute

goldLicense: cc-by

publisherhttps://www.mdpi.com/1422-0067/21/7/2337/pdf?version=1586761500

publisherhttps://www.mdpi.com/1422-0067/21/7/2337/pdf

repositoryhttps://scholarworks.indianapolis.iu.edu/bitstreams/d9026773-e5ea-4102-afeb-d16797df99cc/download

repositoryhttp://dx.doi.org/10.3390/ijms21072337

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7178187

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

ProstateLymphocytes, Tumor-InfiltratingAnimalsMice, TransgenicHumansMiceProstatic NeoplasmsImidazolesQuinolinesProtein Kinase InhibitorsImmunotherapyMaleTOR Serine-Threonine KinasesCTLA-4 AntigenProgrammed Cell Death 1 ReceptorProstatic Neoplasms, Castration-ResistantDasatinibMyeloid-Derived Suppressor CellsImmune Checkpoint Inhibitors

Keywords

DasatinibSrcCastration-resistant Prostate CancerPi3k/mtorCombination ImmunotherapyMitochondrial RespirationImmune Checkpoint BlockadeReverse Phase Protein ArrayDactolisibGranulocytic Myeloid-derived Suppressor CellsMaleProgrammed Cell Death 1 ReceptorMice, TransgenicArticleMiceLymphocytes, Tumor-InfiltratingAnimalsHumansCTLA-4 AntigenImmune Checkpoint InhibitorsProtein Kinase InhibitorsMyeloid-Derived Suppressor CellsTOR Serine-Threonine KinasesImidazolesProstateProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantQuinolinesImmunotherapy

Sustainable Development Goals

SDG 3: 3. Good health

Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib

FAIR Checklist

Authors (3)

Funding (8 grants)

Open Access

Topics

Annotations (Europe PMC)